



Patented Medicine
Prices
Review Board

Since 1987

PMPRB COMMUNIQUE

OTTAWA, April 29, 2009

The Patented Medicine Prices Review Board approves a Voluntary Compliance Undertaking for the medicine Concerta

The Board issued a Notice of Hearing pertaining to allegations of Board Staff that Concerta had been, and was being, sold by Janssen-Ortho Inc. at prices exceeding those indicated by the Board's Excessive Price Guidelines. On April 3, 2009, the Hearing Panel received a Voluntary Compliance Undertaking ("VCU") which proposed to resolve the issues raised in the Notice of Hearing.

The VCU requires, among other things, that Janssen-Ortho offset excess revenues in the amount of \$1,464,441.58 by making a payment to the Government of Canada. By Order of the Board, the proceeding into the price of Concerta is hereby concluded.

The Board Order is a public document and is available on the PMPRB Web site, along with the VCU, under Regulatory; Hearings; Concerta, and under Voluntary Compliance Undertakings.

Concerta is indicated for the treatment of Attention Deficit Hyperactivity Disorder ("ADHD")

Reference:
Sylvie Dupont
Secretary of the Board
Tel: (613) 954-8299; Toll-Free: 1 877 861-2350
E-mail: sylvie.dupont@pmprb-cepmb.gc.ca

The mission of the Patented Medicine Prices Review Board (PMPRB) is to protect consumer interests and contribute to Canadian health care by ensuring that prices of patented medicines are not excessive and by analyzing and reporting to Canadians on price trends of all medicines and on research and development conducted by patentees.

Canada